Quick Answer
PharmaCyte Biotech, Inc. reported Stockholders Equity of $51.89 million for fiscal year 2025.
PharmaCyte Biotech, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $51.89M | +87.7% |
| 2024 | $27.65M | -62.0% |
| 2023 | $72.69M | -19.2% |
| 2022 | $89.92M | +1246.2% |
| 2021 | $6.68M | +31.3% |
| 2020 | $5.09M | +1.0% |
| 2019 | $5.04M | -12.6% |
| 2018 | $5.77M | -28.7% |
| 2017 | $8.09M | +24.0% |
| 2016 | $6.52M | -16.1% |
| 2015 | $7.78M | -13.0% |
| 2014 | $8.94M | +695.6% |
| 2013 | -$1.50M | +34.1% |
| 2012 | -$2.28M | +16.5% |
| 2011 | -$2.73M | -11.3% |
| 2010 | -$2.45M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | $38.11M | -5.3% | +8.2% |
| October 31, 2025 | $35.24M | -18.9% | -19.2% |
| July 31, 2025 | $43.59M | -8.6% | -16.0% |
| April 30, 2025 | $51.89M | +87.7% | +28.9% |
| January 31, 2025 | $40.25M | +28.3% | -7.4% |
| October 31, 2024 | $43.45M | +18.2% | -8.9% |
| July 31, 2024 | $47.71M | +21.7% | +72.6% |
| April 30, 2024 | $27.65M | -62.0% | -11.9% |
- PharmaCyte Biotech, Inc. showed an increase of +87.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2010–2025 period, PharmaCyte Biotech, Inc.’s stockholders equity has grown by 2217.0% (from -$2.45 million to $51.89 million).
- The most recent figure is from PharmaCyte Biotech, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on August 11, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: